IGF-1 LR3 Doses Used in Published Studies: What Researchers Reported

Two of the most common searches around this compound are for an "IGF-1 LR3 dosage calculator" and an "IGF-1 LR3 dosage in IU". Neither request maps onto anything that exists in the published literature. IGF-1 LR3 (long R3 IGF-1) is an analogue of insulin-like growth factor 1 that appears in peer-reviewed research as a tool compound used in tightly controlled animal experiments and in protein-production studies. It is not an approved medicine, and no published trial has established a human dosing framework for it. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or decision.

What follows is a description of what published studies actually administered — the species, the route, the exposure window and what researchers reported as the outcome. It deliberately does not include a dose chart, a conversion table or any suggested amount, because converting an experimental infusion rate in a fetal sheep or a transgenic mouse into a human figure is not a calculation the literature supports.

Why "dosage in IU" does not apply to IGF-1 LR3

International units (IU) are a potency measure defined against an official reference standard, and they exist only for certain biologics where such a standard has been established and adopted. No such IU standard underpins IGF-1 LR3 in the research literature. The published animal work describes administration as a defined experimental exposure in a defined model — for example, an acute intravenous infusion into fetal sheep (PMID 37114757) or intranasal delivery in male 5XFAD mice (PMID 39610283) — rather than as an IU figure intended for people.

Because of that, any online "IU calculator" for this peptide is not translating a published standard. It is applying arithmetic to numbers that have no validated human reference point, which is a different activity from summarising evidence.

Study-by-study: what researchers administered

Continuous IGF-1 LR3 infusion in late-gestation growth-restricted fetal sheep

One of the most directly relevant in vivo investigations examined whether IGF-1 LR3 could promote growth in a sheep model of fetal growth restriction. Researchers administered IGF-1 LR3 to late-gestation growth-restricted sheep fetuses by infusion and reported that the treatment did not promote fetal growth in that model (PMID 39679943). The design point that matters for readers searching for a dose is that the exposure was delivered directly into the fetal circulation of a large-animal model during a specific developmental window, with growth endpoints measured under laboratory conditions (PMID 39679943).

That study is also a useful reminder that a published exposure is not the same thing as a demonstrated benefit. The study's stated conclusion was a negative one for the growth endpoint it tested (PMID 39679943).

Acute IGF-1 LR3 infusion and insulin secretion in fetal sheep

A separate fetal sheep experiment focused on pancreatic islet function rather than growth. Researchers reported that glucose-stimulated insulin secretion was attenuated during an acute IGF-1 LR3 infusion into fetal sheep, and that this attenuation did not persist when islets were subsequently studied in isolation (PMID 37114757). The exposure here was acute — a short infusion administered while the physiological measurements were being made — which is a very different experimental construct from repeated administration over weeks (PMID 37114757).

The in vivo versus ex vivo contrast in that paper is important. An effect observed in the intact animal during infusion disappeared once the islets were removed from the systemic environment, which the study interpreted as the effect not persisting at the isolated-islet level (PMID 37114757). Effects that depend on the whole-body context do not transfer neatly across species, routes or timeframes.

Intranasal long R3 IGF-1 in a mouse model of Alzheimer's disease

A 2025 study used a completely different route. Researchers administered long R3 IGF-1 intranasally to male 5XFAD mice, a transgenic amyloid model, and reported that the treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). The route was chosen to target the central nervous system, the species was mouse, the sex studied was male, and the endpoints were neuropathological and behavioural (PMID 39610283).

This is a clear example of a dissociation between a biomarker change and a functional outcome: a histological signal moved, while the cognitive endpoint did not, according to what the study reported (PMID 39610283).

Recombinant production work, where no dose is administered at all

A substantial share of the LR3 IGF-1 literature is not about dosing at all. One 2023 paper described recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris, a yeast expression system used for producing recombinant proteins (PMID 37261455). No animal or human received a dose in that work; the subject matter was expression strategy and recombinant protein production (PMID 37261455).

Production papers like this matter to the dosing question indirectly. When a compound's literature is dominated by expression, purification and characterisation studies, it indicates a molecule that is still handled as a research reagent rather than a standardised therapeutic with defined potency per unit mass across sources (PMID 37261455).

Summary of study designs (no doses, by design)

Readers who need the exact numeric infusion rates or amounts from these experiments will find them in the full methods sections of the original papers, alongside the animal weights, catheter placements, vehicle composition and measurement schedules that give those numbers meaning. This page does not extract them into a chart, because a number stripped of its model, route and endpoint is not evidence of anything.

Why published study doses do not become recommendations

• Species and developmental stage are part of the dose. Two of the studies used fetal sheep, one during late gestation with growth restriction as the experimental condition (PMID 39679943) and one with acute infusion and islet endpoints (PMID 37114757). Fetal physiology, placental transfer and growth-factor signalling in that context are not interchangeable with adult human physiology.
• Route changes exposure entirely. Intranasal delivery in mice was used to reach the brain (PMID 39610283), whereas intravascular infusion in fetal sheep delivered the compound into the circulation (PMID 37114757). The same nominal amount produces different tissue exposure by route.
• Negative and mixed results are results. One study reported no growth benefit in its model (PMID 39679943) and another reported a pathology change without cognitive preservation (PMID 39610283). Extrapolating an amount from studies whose primary functional endpoints were not met is not a route to a rational protocol.
• No potency standard exists. Material characterisation and production remain active research topics (PMID 37261455), which is inconsistent with the idea that a fixed IU or milligram figure carries the same biological meaning across preparations.
• Human data are absent from this evidence set. None of the verified studies summarised here enrolled human participants, so there is no human tolerability or exposure–response curve to calculate against.

IGF-1 LR3 Physiological Effects in Animal Studies: What Studies Report

Because IGF-1 LR3 acts through insulin-like growth factor signalling, the endpoints researchers monitor often sit close to glucose and insulin physiology. The fetal sheep islet study reported attenuated glucose-stimulated insulin secretion during acute infusion in vivo, with the effect absent once islets were isolated (PMID 37114757). That is a measured physiological change in an animal model, not a catalogued adverse event in people.

In the growth-restricted fetal sheep experiment, the reported outcome was an absence of growth promotion rather than a described benefit (PMID 39679943). In the mouse Alzheimer's model, researchers reported plaque remodeling in the cerebral cortex without preserved cognitive function (PMID 39610283). Taken together, the verified literature describes a compound with measurable biological activity in animal systems and no established human safety dataset. Any statement about human adverse events would go beyond what these papers examined.

Regulatory context

IGF-1 LR3 is not an approved drug product. Material offered under that name is generally labelled research-use-only, meaning it is intended for laboratory investigation and not for human or veterinary administration. Research-use-only material is not manufactured or released to the standards applied to approved injectable medicines, and identity, purity and potency can differ between preparations — a point that recombinant-production research on LR3 IGF-1 makes concrete (PMID 37261455). Insulin-like growth factor signalling itself is the target of approved recombinant IGF-1 medicines prescribed for specific diagnosed conditions, but those are distinct products with their own labelling, and nothing on this page describes their use.

How to read a dosing paper without turning it into a protocol

1. Identify the model first. Note the species, sex, age or gestational stage and any disease model — for instance male 5XFAD mice in the intranasal study (PMID 39610283).
2. Read the route and the delivery hardware. Chronic vascular infusion in a fetal preparation is a specialised surgical model (PMID 39679943).
3. Separate acute from repeated exposure. An acute infusion answers a physiology question, as in the islet study (PMID 37114757), and does not describe long-term exposure.
4. Check which endpoint moved. A histological change and a functional change are not the same finding (PMID 39610283).
5. Check what the material was. Expression system and construct design are part of the experiment (PMID 37261455).

Read this way, the published record on IGF-1 LR3 answers questions about signalling biology in specific animal systems. It does not answer the question that dosage calculators claim to answer. This page is for educational purposes only and is not medical advice; questions about growth factors, metabolism or any health condition belong with a licensed physician.

References

• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)